Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma
ChiCTR-OIC-17013234Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: Overall remission rate. Started Nov 2017; status: recruiting.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-OIC-17013234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013234.